AI주식인사이트AI Stock Insight
B

JW홀딩스

096760KOSPI기타 금융업

64.8 / 100

Reference Date: 2026-07-24

Financial Score25.0 / 40
News Sentiment18.8 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 3.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JW Holdings is a holding company established in 2007 through a spin-off from JW Chungwa Pharmaceutical, overseeing overseas operations and management services for its subsidiaries. In 2025, its revenue decreased by 6.3% to 933 billion won, with key products including nutrient solutions, penem antibiotics, and itraconazole. Major subsidiaries include JW Chungwa Pharmaceutical, JW Shin Yak, and JW Life Science, producing pharmaceuticals, medical devices, and infusion solutions.

Number of Employees

128people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
2.45Industry Average 7.948.0Point

Half of industry avg (excellent)

PBR
0.48Industry Average 0.452.5Point

Higher than industry avg (caution)

ROE
20.70Industry Average 5.457.0Point

3.8x industry avg (excellent)

Debt Ratio
30.24Industry Average 16.990.5Point

1.8x industry avg (risky)

Trend 2023~20257.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲2.4% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲7.9% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 19.3% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position5.0Point

52w mid range (50%)

Current 3,825Won52-week high 4,47052-week low 3,165
1-month return4.0Point

1m +3.38% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-07-22
  • Neutral주식등의대량보유상황보고서(일반)2026-07-03
  • Neutral최대주주등소유주식변동신고서2026-07-03
  • Neutral투자판단관련주요경영사항2026-06-30